DANBURY, Conn., Jan. 31 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. today announced that Jennifer Good, President and Chief Operating Officer of Penwest, is scheduled to discuss the Company at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference. The conference is being held on February 7, 8 and 9, 2006, at the Grand Hyatt Hotel in New York City.
Ms. Good is scheduled to present on Wednesday, February 8, 2006, at 8:00 a.m. Eastern time.
The slides from Penwest’s presentation will be available in the Investor Relations section of the Company’s website at www.penwest.com.
Penwest Pharmaceuticals
Penwest develops pharmaceutical products based on innovative oral drug delivery technologies. We are focusing our development efforts principally on products that address diseases of the central nervous system. The foundation of our technology platform is TIMERx(R), an extended release delivery system that is adaptable to soluble and insoluble drugs and that is flexible for a variety of controlled release profiles. We have also developed two additional oral drug delivery systems, Geminex(R) and SyncroDose(TM). Geminex is a dual drug delivery system that is designed to provide independent release of different active ingredients contained in a drug, and SyncroDose is a drug delivery system that is designed to release the active ingredient of a drug at the desired site and time in the digestive tract.
Contacts: Investors: Media: Diane D’Alessandro Caroline Gentile/Jim Fingeroth (203) 796-3706 Kekst and Company (877) 736-9378 (212) 521-4800
Penwest Pharmaceuticals Co.
CONTACT: Diane D’Alessandro, +1-203-796-3706, 1-877-736-9378; or CarolineGentile or Jim Fingeroth, both of Kekst and Company +1-212-521-4800
Web site: http://www.penwest.com/
